TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

TAKHZYRO Quick Start PROGRAM

Takeda will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations*

3 simple steps to get your patients started right away

1

Print and fill out these 2 FORMS completely:

2

Fax BOTH forms to OnePath® at
1-855-ONEPATH (1-855-663-7284)

3

Let OnePath take it from there

Once BOTH forms are received by OnePath:

Your patient’s dedicated Patient Support Manager will call your patient promptly to:

  • Confirm all forms are complete
  • Coordinate shipment of TAKHZYRO

The benefits investigation will be conducted. Prior authorization/appeal, if required, will begin.

A 1-month supply of TAKHZYRO will be shipped to your patient once eligibility requirements have been confirmed and the specialty pharmacy verifies the prescription with your office. At this time, a specially trained nurse will call the patient to schedule self-administration training.

Once your patient's commercial insurance coverage for TAKHZYRO is approved, he/she will no longer be eligible for the Quick Start Program.

Once eligibility has been confirmed, a 1-month supply of TAKHZYRO will be shipped to your patients. Patients are eligible for up to 2 months of product at no cost, with the potential for an approval process for continued supply of the product after the second month.

Note that insurance companies sometimes require additional documentation to authorize coverage for TAKHZYRO, which could include:

Statement of Medical Necessity

Letter of Intent to Treat

Coverage Denial Letter

Formulary Exception Letter

Claim Denial Letter

OnePath® logo

Explore OnePath® support

Learn more about product support available through OnePath.

View Services

Browse resources

Find educational materials and helpful information for patients and your practice.

See Resources

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.